Plainsboro, New Jersey, September 24, 2002-- Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that its Integra NeuroSciences division has begun marketing the Helitene® Absorbable Collagen Hemostatic Agent in a 35mm x 70mm pad form. The product received a PMA supplement approval from the United States Food and Drug Administration for an indication for use in surgical procedures with the added flexibility of a pad form as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.

The Helitene® product in a pad form is the compressed form of the Helitene® Microfibrillar product that has been marketed by Integra for surgical applications for over 15 years. The Helitene® products effectively control bleeding within two to five minutes when applied directly to the bleeding site and are designed to be totally absorbable if left in situ after hemostasis. The product is also available in two fibrillar form sizes, 0.5 gram and 1.0 gram.

"Our Integra NeuroSciences sales force now can offer our Helitene fibrillar collagen hemostatic agent in an alternative configuration, which we believe will make the product line more attractive to surgeons, including neurosurgeons," commented Deborah Leonetti, Vice President of Marketing.

Integra NeuroSciences, the neurosurgical division of Integra LifeSciences Holdings Corporation, will now be able to sell the Helitene® product in the pad or fibrillar form into the neurosurgery market in the United States through its direct sales force. The launch activities for the Helitene® pad product are coinciding with the Congress of Neurological Surgeons meeting being held in Philadelphia this week.

Integra NeuroSciences designs, manufactures and sells implants, instruments and monitors used in neurosurgery and intensive care units, primarily for the treatment of neurological trauma and surgery. In the United States, Integra NeuroSciences sells through 63 direct sales territories staffed by personnel called neurospecialists, seven regional managers, and ten clinical development specialists who educate and train both neurospecialists and customers in the use of Integra's products. Integra also sells through a direct sales force in the United Kingdom, France, Germany and Belgium. In the rest of the world, Integra NeuroSciences' products are sold though specialized neurosurgical distributors and dealers.

Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world. Integra has approximately 750 permanent employees. Please feel free to visit Integra's website at (http://www.integra-LS.com).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements relating to the sale of the Helitene® product for use in new therapeutic applications and the marketing of this product to a new class of customers. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to adopt new products may affect the use of the Helitene® product in new therapeutic applications, and the resources and efforts expended on marketing the Helitene® product may affect sales of the product to a new class of customers. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2001 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

SOURCE: Integra LifeSciences Holdings Corporation

Contacts:
Integra LifeSciences Holdings Corporation
John B. Henneman, III
Senior Vice President
Chief Administrative Officer
609-936-2481
jhenneman@Integra-LS.com

John Bostjancic
Senior Director of Finance
609-936-2239
jbostjancic@Integra-LS.com